Europe Psychedelic Drugs Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Feb 2020
  • Europe
  • 350 Pages
  • No of Tables: 122
  • No of Figures: 58

Europe Psychedelic Drugs Market By Source (Synthetic, Natural), Type (Dissociatives, Empathogens, Serotonergic (Classical Psychedelic Drugs)), Application (Narcolepsy, Treatment-Resistant Depression, Post-Traumatic Stress Disorder (PTSD), Major Depressive Disorder, Others), Route of Administration (Oral, Intranasal, Parenteral, Others), Drugs (Gamma Hydroxybutyric Acid (GHB), Ketamine, 3,4-Methylenedioxymethamphetamine (Ecstasy), Psilocybin), End User (Hospitals, Speciality Clinic, Research Organization, Others), Distribution Channel (Hospital Pharmacy, Compounding Pharmacy, Others), Country (Germany, France, United Kingdom, Italy, Spain, Switzerland, Russia, Netherlands, Belgium, Denmark, Rest of Europe) - Industry Trends and Forecast to 2027

Europe Psychedelic Drugs Market

Market Analysis and Insights: Europe Psychedelic Drugs Market

Psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 15.0% in the forecast period of 2020 to 2027 and expected to reach USD 361.13 million by 2027. Growing acceptance of psychedelic drugs for treating depression and increasing prevalence of depression and mental disorders are the factors accelerating the market growth.

Mental health is important for living a balanced and healthy life. Mental health encompasses emotional, psychological and social well-being and affects the person's feelings, thinking ability and behaviour. Mental health also supports decision making.  Due to the increase in mental disorders in America and Europe, various non-profit, governmental, non-governmental, national and international organizations conduct mental health awareness programs, advertising campaigns, provocative television programs that illustrate how to support mental health in Europe

For instance,

  • Europeans are afflicted with mental and neurological diseases, with approximately 165 million people or 38% of the population suffering from a brain disorder such as depression, anxiety, insomnia or dementia each year

Awareness campaigns have encouraged people to select appropriate treatment for mental disorder procedures and professionals which is increasing the demand for psychedelic drugs. For this reason, growing awareness of mental health is acting as a driver for the psychedelic drug market in Europe.

This Psychedelic Drugs Market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Europe Psychedelic Drugs Market

Europe Psychedelic Drugs Market Scope and Market Size

Psychedelic drugs market is segmented on the basis of source, type, application, route of administration, drugs, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of source, the market is segmented into synthetic and natural. Synthetic psychedelic drugs dominate in the psychedelic drugs market since all available drugs are originated from synthetic source. For this reason, the synthetic segment dominates the market and will also grow at a higher rate over the expected period.
  • On the basis of type, the market is segmented into dissociatives, empathogens, and serotonergic (classical psychedelic drugs). The dissociative segment holds largest share in the psychedelic drugs market as XYREM (sodium oxybate, Jazz Pharmaceuticals Inc.) is the only approved drug of dissociative psychedelic substances for the treatment of narcolepsy.
  • On the basis of application, the market is segmented into narcolepsy, treatment-resistant depression, post-traumatic stress disorder (PTSD), major depressive disorder, others. Sodium oxybate as a derivative of gamma hydroxybutyric acid (GHB) leads in the market for psychedelic drugs and mainly uses psychedelic medicine and the drug has been approved for narcolepsy. For this reason, the narcolepsy segment dominates the psychedelic drug market.
  • On the basis of route of administration, the market is segmented into oral, intranasal, parenteral, others. Oral administration of the drug is highly convenient for patients as compared to other forms. Oral is dominant in the psychedelic drug market as Xyrem is the most brand-name drug available on the market in oral dosage forms. In addition, patient adherence is very important in the symptomatic treatment of the disease. Oral administration of the drug is very convenient for patients compared to other forms.
  • On the basis of drugs, the market is segmented into gamma hydroxybutyric acid (GHB), ketamine, 3,4-methylenedioxymethamphetamine (ecstasy), psilocybin. Gamma hydroxybutyric acid (GHB) dominates the psychedelic drug market since Xyrem is primarily a psychedelic drug and falls into this category. For this reason, the gamma hydroxybutyric acid (GHB) segment dominates the market for psychedelic drugs.
  • On the basis of end user, the market is segmented into hospitals, speciality clinic, research organisation, others. Hospitals dominate the psychedelic drug market due to the high load of patients and most medicines are administered under the supervision of a doctor. For this reason, the hospital segment dominates the psychedelic drug market.
  • On the basis of distribution channel, the market is segmented into hospital pharmacy, compounding pharmacy, others. The hospital pharmacy has the largest market share as these medicines treat more patients in hospitals, the demand for medicines increases in the hospital pharmacy

Europe Psychedelic Drugs Market

Psychedelic Drugs Market Country Level Analysis

Psychedelic drugs market is analysed and market size information is provided by country, source, type, application, route of administration, drugs, end user and distribution channel as referenced above.

According to WHO data, 25% of the population suffers from depression or anxiety every year. The burden of the disease is 19.5% in the European region and 26% in the European Union (EU) countries. Germany dominates the European market due to the increase in technologically advanced health systems and the growing cases of depression in the country. The growing number of depressing patients and increasing awareness conducted by the government authorities are boosting the market growth in Italy. Psychedelic drugs are highly consumed for the treatment of narcolepsy and in UK it is expected that 30,000 people are suffering from narcolepsy, due to this reason UK is growing in the Europe psychedelic drugs market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Increasing R&D Activities in Psychedelic Drugs is Creating New Opportunities for Manufacturers in Europe Psychedelic Drugs Market

Psychedelic drugs market also provides you with detailed market analysis for every country growth in aesthetic industry with psychedelic drugs sales, impact of advancement in the psychedelic drugs and changes in regulatory scenarios with their support for the psychedelic drugs market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Psychedelic Drugs Market Share Analysis

Psychedelic drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Europe psychedelic drugs market.

The major players covered in the report are Johnson & Johnson Services, Inc., Jazz Pharmaceuticals, Inc., Celon Pharma SA, COMPASS, usonainstitute.org, Develco pharma schweiz ag , Doughlas pharmaceuticals limited, NeuroRX, Inc., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals, LLC., AVADEL PHARMACEUTICALS, PLC among other players in the Europe DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and developments are also initiated by the companies worldwide which are also accelerating the psychedelic drugs market.

For instance,

  • In December 2019, the company received approval for the marketing of SPRAVATO across Europe. This drug is used in combination with SSRIs and SNRIs to treat resistant depression. Marketing SPRAVATO as a nasal spray will increase the company's revenue generation.
  • In January 2020, Jazz Pharmaceuticals, Inc. received marketing authorization for solriamfetol (Sunosi) for excessive daytime sleepiness in adults with narcolepsy. The main advantage is the increase in the company's revenue generation.

Clinical study data sets, authorization, collaboration, joint ventures and other strategies by the market players is enhancing the market in the Europe psychedelic drugs market also provides the benefit for organisation to improve their offering for psychedelic drugs.

Customization Available: Europe Psychedelic Drugs Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

TABLE 1 PSYCHEDELICS RESEARCHES IN EUROPE

TABLE 2 MENTAL ILLNESS IN U.S. ADULTS IN 2018

TABLE 3 MENTAL DISORDERS IN U.S. ADULTS IN 2018

TABLE 4 MORE THAN ONE IN SIX PEOPLE IN EU COUNTRIES HAVE A MENTAL HEALTH PROBLEM

TABLE 5 MEN ARE MORE LIKELY TO DIE FROM SUICIDE IN ALL EU COUNTRIES

TABLE 6 MENTAL DISORDERS CAUSED BY USAGE OF SUBSTANCE DISORDERS IN WORLD IN 2017

TABLE 7 DRUG DEVELOPMENT PATHWAY FOR FDA APPROVAL OF NEW MEDICATIONS

TABLE 8 THE 1971 UN CONVENTION ON PSYCHOTROPIC SUBSTANCES

TABLE 9 COST OF PSYCHEDELIC DRUGS

TABLE 10 TOTAL COSTS (DIRECT AND INDIRECT) OF MENTAL HEALTH PROBLEMS IN EU COUNTRIES, IN MILLION AND AS A SHARE OF GDP, 2015

TABLE 11 PSYCHEDELIC DRUGS R&D ACTIVITIES

TABLE 12 EUROPE PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2018-2027 (USD MILLION)

TABLE 13 EUROPE SYNTHETIC IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 14 EUROPE NATURAL IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 15 EUROPE PSYCHEDELIC DRUGS MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 16 EUROPE DISSOCIATIVE IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 17 EUROPE EMPATHOGENS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 18 EUROPE SEROTONERGIC (CLASSICAL PSYCHEDELIC DRUGS) IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 19 EUROPE PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 20 EUROPE NARCOLEPSY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 21 EUROPE TREATMENT- RESISTANT DEPRESSION (TRD) IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 22 EUROPE POST-TRAUMATIC STRESS DISORDER (PTSD) IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 23 EUROPE MAJOR DEPRESSIVE DISORDER IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 24 EUROPE OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 25 EUROPE PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 26 EUROPE ORAL IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 27 EUROPE INTRANASAL IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 28 EUROPE PARENTERAL IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 29 EUROPE OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 30 EUROPE PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2018-2027 (USD MILLION)

TABLE 31 EUROPE GAMMA-HYDROXYBUTYRIC ACID (GHB) IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 32 EUROPE KETAMINE IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 33 EUROPE 3,4-METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY) IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 34 EUROPE PSILOCYBIN IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 35 EUROPE PSYCHEDELIC DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 36 EUROPE HOSPITALS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 37 EUROPE SPECIALITY CLINIC IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 38 EUROPE RESEARCH ORGANIZATION IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 39 EUROPE OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 40 EUROPE PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 41 EUROPE HOSPITAL PHARMACY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 42 EUROPE COMPOUNDING PHARMACY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 43 EUROPE OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 44 EUROPE PSYCHEDELIC DRUGS MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 45 EUROPE PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2018-2027 (USD MILLION)

TABLE 46 EUROPE PSYCHEDELIC DRUGS MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 47 EUROPE PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 48 EUROPE PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 49 EUROPE PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2018-2027 (USD MILLION)

TABLE 50 EUROPE PSYCHEDELIC DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 51 EUROPE PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 52 GERMANY PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2018-2027 (USD MILLION)

TABLE 53 GERMANY PSYCHEDELIC DRUGS MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 54 GERMANY PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 55 GERMANY PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 56 GERMANY PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2018-2027 (USD MILLION)

TABLE 57 GERMANY PSYCHEDELIC DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 58 GERMANY PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 59 FRANCE PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2018-2027 (USD MILLION)

TABLE 60 FRANCE PSYCHEDELIC DRUGS MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 61 FRANCE PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 62 FRANCE PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 63 FRANCE PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2018-2027 (USD MILLION)

TABLE 64 FRANCE PSYCHEDELIC DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 65 FRANCE PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 66 UNITED KINGDOM PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2018-2027 (USD MILLION)

TABLE 67 UNITED KINGDOM PSYCHEDELIC DRUGS MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 68 UNITED KINGDOM PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 69 UNITED KINGDOM PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 70 UNITED KINGDOM PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2018-2027 (USD MILLION)

TABLE 71 UNITED KINGDOM PSYCHEDELIC DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 72 UNITED KINGDOM PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 73 ITALY PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2018-2027 (USD MILLION)

TABLE 74 ITALY PSYCHEDELIC DRUGS MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 75 ITALY PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 76 ITALY PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 77 ITALY PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2018-2027 (USD MILLION)

TABLE 78 ITALY PSYCHEDELIC DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 79 ITALY PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 80 SPAIN PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2018-2027 (USD MILLION)

TABLE 81 SPAIN PSYCHEDELIC DRUGS MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 82 SPAIN PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 83 SPAIN PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 84 SPAIN PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2018-2027 (USD MILLION)

TABLE 85 SPAIN PSYCHEDELIC DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 86 SPAIN PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 87 SWITZERLAND PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2018-2027 (USD MILLION)

TABLE 88 SWITZERLAND PSYCHEDELIC DRUGS MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 89 SWITZERLAND PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 90 SWITZERLAND PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 91 SWITZERLAND PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2018-2027 (USD MILLION)

TABLE 92 SWITZERLAND PSYCHEDELIC DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 93 SWITZERLAND PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 94 RUSSIA PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2018-2027 (USD MILLION)

TABLE 95 RUSSIA PSYCHEDELIC DRUGS MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 96 RUSSIA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 97 RUSSIA PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 98 RUSSIA PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2018-2027 (USD MILLION)

TABLE 99 RUSSIA PSYCHEDELIC DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 100 RUSSIA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 101 NETHERLANDS PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2018-2027 (USD MILLION)

TABLE 102 NETHERLANDS PSYCHEDELIC DRUGS MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 103 NETHERLANDS PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 104 NETHERLANDS PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 105 NETHERLANDS PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2018-2027 (USD MILLION)

TABLE 106 NETHERLANDS PSYCHEDELIC DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 107 NETHERLANDS PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 108 BELGIUM PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2018-2027 (USD MILLION)

TABLE 109 BELGIUM PSYCHEDELIC DRUGS MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 110 BELGIUM PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 111 BELGIUM PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 112 BELGIUM PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2018-2027 (USD MILLION)

TABLE 113 BELGIUM PSYCHEDELIC DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 114 BELGIUM PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 115 DENMARK PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2018-2027 (USD MILLION)

TABLE 116 DENMARK PSYCHEDELIC DRUGS MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 117 DENMARK PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2018-2027 (USD MILLION)

TABLE 118 DENMARK PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 119 DENMARK PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2018-2027 (USD MILLION)

TABLE 120 DENMARK PSYCHEDELIC DRUGS MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 121 DENMARK PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 122 REST OF EUROPE PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2018-2027 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19